---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-009762"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:50:26.987315+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q4 revenue $19.3M, up 26% YoY; net loss narrows to $2.4M; guides FY2023 sales $78-82M

## Summary
- Q4 2022 revenue $19.3M (+26% YoY); full-year revenue $72.8M (+17.6% YoY), highest ever.
- Net loss Q4 $2.4M ($0.20/share) vs $8.9M ($1.05) in Q4 2021; full-year net loss $18.7M ($1.89) vs $32.7M ($3.83).
- Debt reduced to $10.0M at year-end from $21.6M at end of 2021; cash used in ops improved to $17.4M from $33.5M.
- 2023 guidance: net sales $78-82M, gross profit $7-9M; focus on hemodialysis concentrates growth and profitability.
- Reacquired distribution rights from Baxter for >700 hemodialysis customers; new CEO Mark Strobeck joined July 2022.

## SEC filing metadata
- accession: 0001628280-23-009762
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/rmti-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-009762
- JSON: https://secwatch.observer/filing/0001628280-23-009762.json
- Plain text: https://secwatch.observer/filing/0001628280-23-009762.txt

## Key facts
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported 2023 results: revenue $78.0 Million to $82.0 Million. Guidance initiated.
  - Period: 2023
  - Revenue: $78.0 Million to $82.0 Million
  - Guidance: initiated
  - Result: guidance update
  source text: Rockwell projects its 2023 guidance as follows: Net Sales $78.0 Million to $82.0 Million Gross Profit $7.0 Million to $9.0 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2022 results: revenue $72.8 million, net income $18.7 million, EPS $1.89 per share.
  - Period: the twelve months ended December 31, 2022
  - Revenue: $72.8 million
  - Net income: $18.7 million
  - EPS: $1.89 per share
  - Result: reported results
  source text: of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6% increase year-over-year and the highest full-year revenue to date for the Company • Reduced debt to $10.0 million at December 31, 2022, representing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2022 results: revenue $19.3 million, net income $2.4 million, EPS $0.20 per share.
  - Period: the three months ended December 31, 2022
  - Revenue: $19.3 million
  - Net income: $2.4 million
  - EPS: $0.20 per share
  - Result: reported results
  source text: --- Rockwell Medical Announces Fourth Quarter and Full-Year 2022 Financial and Operational Results • Achieved third consecutive quarter of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000162828023009762/0001628280-23-009762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.